Tumor budding in tumor tissue among operatively treated patients with lung adenocarcinoma

Milena Vasilijević; Aleksandra Lovrenski; Milana Panjković

doi:10.2298/VSP190522091V

Milena Vasilijević University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Aleksandra Lovrenski University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Milana Panjković University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP190522091V

Keywords: lung neoplasms, adenocarcinoma, neoplasm invasiveness, neoplasm staging, postoperative period, neoplasm recurrence, local

Abstract

Background/Aim. The histological phenomenon of tumor budding is being recognized as an important determinant of disease progression and poor prognosis in various types of carcinoma. We aimed to evaluate the clinicopathological significance of tumor budding in adenocarcinoma of the lung. Methods. The study included 114 patients operatively treated for lung adenocarcinoma in a one-year period. Microscopic analysis of routine histological slides was performed to establish the presence and density of tumor buds. These results were compared in relation to gender, age, tumor size, nodal status, and pathological stage. Results. The budding-positive group included 34 (53.1%) men and 27 (54%) women. There were 30 (46.9%) men and 23 (46%) women in the budding-negative group. No statistical significant difference in age was found between males (64.3 ± 6.59 years) and females (63.1 ± 6.53 years) in the budding-positive group, nor in the budding-negative group (males 63.3 ± 6.02 years; females 63.2 ± 6.72 years). Statistically significant result in tumor size was found in females with the presence of tumor budding (p < 0.05). The budding-positive group of patients in nodal stage N1 and stage III of the disease pointed to the statistical significance (p < 0.05). Conclusion. With the statistical significance confirmed between the higher nodal status, higher pathological stage, and tumor budding found in this study, this histological phenomenon is still relatively new for the diagnostics domain of pathology. However, it increasingly receives attention as an adverse prognostic factor. These results may help tumor budding incorporate into the existing staging systems in addition to other factors known to be predictors of worse outcome.

References

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277‒300.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9‒29.

Kerr KM. Personalized medicine for lung cancer: new challeng-es for pathology. Histopathology 2012; 60(4): 531–46.

Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of pa-tients with lung adenocarcinoma. Nat Med 2002; 8(8): 816–24.

Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10: 1001–10.

Šolajić N. Prognostic significance of density of tumor buds and cytoplasmic pseudofragments in stage II colonic carcinoma [dissertation]. Novi Sad: Faculty of Medicine, University of Novi Sad; 2016. (Serbian)

Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009; 119(6): 1420–8.

Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of chang-ing cell state in development and disease. J Clin Invest 2009; 119(6): 1438‒49.

Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as on-cotarget. Oncotarget 2010; 1(7): 651‒61.

Kalluri R. EMT: when epithelial cells decide to become mes-enchymal- like cells. J Clin Invest 2009; 119(6): 1417‒9.

Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer—ready for diagnostic practice? Human Pathology 2016; 47(1): 4‒19.

Dawson H, Lugli A. Molecular and pathogenetic aspects of tu-mor budding in colorectal cancer. Front Med (Lausanne) 2015; 2: 11.

Masuda R, Kijima H, Imamura N, Aruga N, Nakamura Y, Masu-da D, et al. Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 2012; 6(5): 937‒43.

Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferen-tiation: an important step in tumor invasion. Clin Exp Metas-tasis 1985; 3(4): 257–79.

Prall F. Tumour budding in colorectal adenocarcinoma. His-topathology 2007; 50(1): 151‒62.

Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour “budding” as an index to estimate the potential of aggressive-ness in rectal cancer. Histopathology 2002; 40(2): 127‒32.

Sy J, Fung CL, Dent OF, Chapius PH, Bokey L, Chan C. Tumor budding and survival after potentially curative resection of node- positive colon cancer. Dis Colon Rectum 2010; 53(3): 301‒7.

Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Modern Patholo-gy 2012; 25(10): 1315‒25.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Clas-sification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J Thorac Oncol 2015; 10(9): 1243–60.

Eguchi T, Kadota K, Park BJ, Travis WD, Jones DR, Adusumilli PS, et al. The New IASLC/ATS/ERS Lung Adenocarcinoma Classification: what the surgeon should know. Semin Thorac Cardiovasc 2014; 26(3): 210‒22.

Imai T. The growth of human carcinoma: a morphological analysis. Fukuoka Igaku Zasshi 1954; 45: 72‒102.

Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tu-mor Budding: The Name is EMT. Partial EMT. J Clin Med 2016; 5(5): pii: E51.

Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or mod-erately differentiated colon adenocarcinoma. Dis Colon Rec-tum 2003; 46(10): 1400‒6.

Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anti-cancer Res 2005; 25(2B): 1269‒72.

Prall F, Nizze H, Barten M. Tumour budding as prognostic fac-tor in stage I/II colorectal carcinoma. Histopathology 2005; 47(1): 17–24.

Zlobec I, Hädrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, et al. Intratumoural budding (ITB) in preoperative biop-sies predicts the presence of lymph node and distant metasta-ses in colon and rectal cancer patients. Br J Cancer 2014; 110(4): 1008‒13.

Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson G, Dirschmid K, et al. Tumor budding in colorectal cancer revisit-ed: Results of a multicenter interobserver study. Virchows Arch 2015; 466(5): 485–93.

Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 1993; 36(7): 627–35.

Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of me-tastasis to the lung and liver after curative excision of colorec-tal cancer. Hepatogastroenterology 2005; 52(65): 1432‒5.

Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hy-land J, et al. Tumor budding is a strong and reproducible prog-nostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1): 134–41.

Kadota K, Yeh Y, Villena-Vargas J, Cherkassky L, Drill EN, Si-ma CS, et al. Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest 2015; 148(3): 711‒21.

Yu K, Zhang C, Berry GJ, Altman RB, Re C, Rubin DL, et al. Predicting non-small cell lung cancer prognosis by fully auto-mated microscopic pathology image features. Nat Commun 2016; 7: 12474.

Yamaguchi Y, Ishii G, Kojima M, Yoh K, Otsuka H, Otaki Y, et al. Histopathologic Features of the Tumor Budding in Adeno-carcinoma of the Lung. Tumor Budding As an Index to Pre-dict the Potential Aggressiveness. J Thorac Oncol 2010; 5: 1361‒8.

Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011; 40(7): 545–51.

O’Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, et al. Tumor budding is an independent ad-verse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015; 39(4): 472–8.

Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, et al. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 2013; 49(5): 1032‒9.

Salhia B, Trippel M, Pfaltz K, Cihoric N, Grogg A, Lädrach C, et al. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat 2015; 150(2): 363‒71.

Almangush A, Salo T, Hagström J, Leivo I. Tumour budding in head and neck squamous cell carcinoma - a systematic review. Histopathology 2014; 65(5): 587‒94.

Manjula BV, Augustine S, Selvam S, Mohan AM. Prognostic and predictive factors in gingivo buccal complex squamous cell carcinoma: role of tumor budding and pattern of invasion. In-dian J Otolaryngol Head Neck Surg 2015; 67(1): 98–104.